The Promise of Interferon-Free Treatment Regimens for Hepatitis C

Published Online: Friday, February 24, 2012
Follow Pharmacy_Times:
In a podcast from the American Gastroenterological Association, Anna S. Lok, MD, a professor in the department of internal medicine at the University of Michigan Health System, discussed an editorial titled “Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?” that she coauthored in the December 2011 issue of Gastroenterology.
 
For approximately a decade up until 2011, the standard treatment for hepatitis C was a combination of interferon and ribavirin. The direct-acting antiviral agents telaprevir and boceprevir were approved last year as part of a triple-therapy regimen including interferon and ribavirin. In the interview, however, Dr. Lok explained that progress toward treating hepatitis C without interferon is proceeding very quickly.
 
Many hepatitis C patients are unable to tolerate interferon due to side effects, Dr. Lok explained, although clinicians also hope that an interferon-free treatment regimen could allow for a shorter duration of treatment and produce a higher response rate. She said that there are numerous trials underway to test interferon-free regimens and that some have already shown promising results. Pending the results of Phase 3 trials that should begin soon, Dr. Lok estimated that interferon-free regimens could be available within 3 to 5 years.
 
To listen to the interview, click here.
Related Articles
Since 2007, the pharmaceutical industry, several professional societies, and the FDA have collaborated on initiatives designed to limit the use of OTC cough and cold medications in young children.
Two cofounders of a Massachusetts compounding pharmacy, plus 12 other former employees, have been arrested for allegedly distributing tainted drugs that caused a fungal meningitis outbreak in 2012, killing 64 individuals.
Cedarville University third-year doctor of pharmacy students have been partnering with hospitals in the Dayton-Kettering region to administer influenza vaccines to employees.
Latest Issues
$auto_registration$